IQVIA (IQV) is a publicly traded Healthcare sector company. As of November 17, 2026, IQV trades at $261.84 with a market cap of $43.69B and a P/E ratio of 31.75. IQV moved -1.09% today. Year to date, IQV is +17.51%; over the trailing twelve months it is +20.05%. Its 52-week range spans $134.65 to $284.50. Analyst consensus is strong buy with an average price target of $314.14. Rallies surfaces IQV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IQVIA beats Q3 estimates as bookings rise and 2026 guidance increases: IQVIA’s Q3 revenue rose 8% to $4.43 billion, above the $4.37 billion consensus, while adjusted diluted EPS increased 11% to $3.34, above the $3.28 estimate. R&D Solutions net new bookings grew 15% to $3.2 billion, and IQVIA raised its 2026 revenue, adjusted EBITDA and adjusted EPS outlooks.
| Metric | Value |
|---|---|
| Price | $261.84 |
| Market Cap | $43.69B |
| P/E Ratio | 31.75 |
| EPS | $8.12 |
| Dividend Yield | 0.00% |
| 52-Week High | $284.50 |
| 52-Week Low | $134.65 |
| Volume | 312 |
| Avg Volume | 0 |
| Revenue (TTM) | $16.98B |
| Net Income | $1.38B |
| Gross Margin | 0.00% |
15 analysts cover IQV: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $314.14.